Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
The FDA cleared tucatinib with trastuzumab and pertuzumab for maintenance after induction treatment in adults with unresectable locally advanced or metastatic HER2-positive disease.
TL;DR
- The FDA approved tucatinib with trastuzumab and pertuzumab for maintenance treatment of certain adults with HER2-positive advanced breast cancer.
- The decision followed induction treatment and was supported by the randomized HER2CLIMB-05 study of 654 patients.
- The FDA reported median progression-free survival of 24.9 months with tucatinib versus 16.3 months with placebo; overall survival data remain immature.
The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer after induction treatment. Pfizer announced the approval on October 7. [1][2] [1] [2]
The FDA said efficacy was evaluated in HER2CLIMB-05, a randomized, double-blind, placebo-controlled study involving 654 adults who had no disease progression after four to eight cycles of induction treatment. Patients received tucatinib or placebo alongside trastuzumab and pertuzumab. [1] [1]
The FDA reported median investigator-assessed progression-free survival of 24.9 months in the tucatinib group and 16.3 months in the placebo group. Pfizer’s announcement reported the same trial result and characterized the regimen as a chemotherapy-free maintenance option. [1][2] [1] [2]
The FDA noted that overall survival data were immature at the analysis and that the safety profile was consistent with known risks of the medicines. The approval applies to the specified population and treatment sequence; it does not establish outcomes for patients outside those criteria. [1] [1]
Why it matters
The decision moves a three-drug regimen into a first-line maintenance setting for a defined HER2-positive population, with the FDA’s review tied to a randomized trial and a specified treatment sequence.
Editor's note
Regulatory reporting only. The label and full prescribing information govern the approved population and safety information.